Massachusetts Financial Services Co. MA Purchases 10,366 Shares of Ascendis Pharma A/S (NASDAQ:ASND)

Massachusetts Financial Services Co. MA raised its stake in Ascendis Pharma A/S (NASDAQ:ASND - Free Report) by 0.6% during the 1st quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm owned 1,877,917 shares of the biotechnology company's stock after purchasing an additional 10,366 shares during the quarter. Massachusetts Financial Services Co. MA owned about 3.08% of Ascendis Pharma A/S worth $292,692,000 at the end of the most recent quarter.

Several other hedge funds also recently added to or reduced their stakes in the stock. RA Capital Management L.P. increased its position in shares of Ascendis Pharma A/S by 4.1% during the fourth quarter. RA Capital Management L.P. now owns 10,112,744 shares of the biotechnology company's stock worth $1,392,221,000 after acquiring an additional 402,316 shares during the last quarter. Avoro Capital Advisors LLC boosted its stake in Ascendis Pharma A/S by 2.3% in the fourth quarter. Avoro Capital Advisors LLC now owns 5,103,055 shares of the biotechnology company's stock valued at $702,538,000 after acquiring an additional 114,167 shares during the period. Artisan Partners Limited Partnership boosted its position in shares of Ascendis Pharma A/S by 0.9% during the fourth quarter. Artisan Partners Limited Partnership now owns 4,450,420 shares of the biotechnology company's stock worth $612,689,000 after buying an additional 39,309 shares during the period. Janus Henderson Group PLC boosted its position in shares of Ascendis Pharma A/S by 4.6% during the fourth quarter. Janus Henderson Group PLC now owns 4,380,382 shares of the biotechnology company's stock worth $602,910,000 after buying an additional 193,688 shares during the period. Finally, Capital International Investors boosted its position in shares of Ascendis Pharma A/S by 35.7% during the fourth quarter. Capital International Investors now owns 2,863,249 shares of the biotechnology company's stock worth $394,183,000 after buying an additional 753,859 shares during the period.

Wall Street Analyst Weigh In

A number of equities research analysts have weighed in on the company. Royal Bank Of Canada upped their target price on Ascendis Pharma A/S from $205.00 to $210.00 and gave the stock an "outperform" rating in a research report on Friday, May 2nd. Evercore ISI boosted their target price on shares of Ascendis Pharma A/S from $260.00 to $280.00 and gave the company an "outperform" rating in a research note on Friday, May 2nd. Wedbush increased their price objective on Ascendis Pharma A/S from $181.00 to $212.00 and gave the stock an "outperform" rating in a report on Friday, May 2nd. Bank of America increased their price objective on Ascendis Pharma A/S from $201.00 to $216.00 and gave the stock a "buy" rating in a report on Monday, June 9th. Finally, Oppenheimer reissued an "outperform" rating and set a $224.00 target price (up from $215.00) on shares of Ascendis Pharma A/S in a research report on Friday, June 13th. One equities research analyst has rated the stock with a hold rating and fifteen have given a buy rating to the stock. Based on data from MarketBeat.com, Ascendis Pharma A/S has a consensus rating of "Moderate Buy" and an average target price of $223.07.

Ascendis Pharma A/S Stock Down 2.8%

ASND stock traded down $5.05 during trading on Friday, reaching $172.16. The stock had a trading volume of 426,823 shares, compared to its average volume of 505,205. The company has a market capitalization of $10.52 billion, a price-to-earnings ratio of -27.41 and a beta of 0.38. Ascendis Pharma A/S has a one year low of $111.09 and a one year high of $183.00. The company's 50 day moving average is $169.23 and its two-hundred day moving average is $154.43.

Ascendis Pharma A/S (NASDAQ:ASND - Get Free Report) last announced its quarterly earnings results on Thursday, May 1st. The biotechnology company reported ($1.66) EPS for the quarter, missing analysts' consensus estimates of ($1.56) by ($0.10). The company had revenue of $123.97 million for the quarter, compared to the consensus estimate of $98.56 million. As a group, research analysts predict that Ascendis Pharma A/S will post -4.34 earnings per share for the current fiscal year.

Ascendis Pharma A/S Profile

Ascendis Pharma A/S, a biopharmaceutical company, focuses on developing therapies for unmet medical needs. It offers SKYTROFA for treating patients with growth hormone deficiency (GHD). The company is also developing a pipeline of three independent endocrinology rare disease product candidates in clinical development, as well as focuses on advancing oncology therapeutic candidates.